PILLSBURY WINTHROP SHAW PITTMAN LLP Hugh M. Ray, III 609 Main Street, Suite 2000 Houston, Texas 77002 Tel: (713) 276-7600 hugh.ray@pillsburylaw.com

Counsel for Sentynl Therapeutics, Inc. [additional counsel at end of document]

IN THE UNITED STATES BANKRUPTCY COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

In re: Chapter 11

EIGER BIOPHARMACEUTICALS, INC., Case No. 24-80040 (SGJ) et al.

Debtors.

(Jointly Administered)

REPLY IN SUPPORT OF MOTION FOR ALLOWANCE OF ADMINISTRATIVE EXPENSE CLAIM OF SENTYNL THERAPEUTICS, INC.

TABLE OF CONTENTS

PRELIMINARY STATEMENT	1
DETAILS OF THE SUPPLY CHAIN	8
A. Commercial Drug Manufacturing Overview	8
В.	10
C.	
	11
D	13
E	15
FURTHER REPLY IN SUPPORT OF MOTION FOR ALLOWANCE	16
A.	16
В.	18
C.	
С.	
CONCLUSION	20
CERTIFICATE OF SERVICE	22

TABLE OF AUTHORITIES

Cases

Kroboth v. Brent,	
625 N.Y.S.2d 748 (N.Y. Sup. Ct. A.D.1995)	3
Landmark Ventures, Inc. v. H5 Techs., Inc.,	
58 N.Y.S.3d 591 (N.Y. Sup. Ct. A.D. 2017)	19
Trireme Energy Holdings, Inc. v. Innogy Renewables US LLC,	
No. 1:20-CV-05015 (JLR), 2023 WL 8643799 (S.D.N.Y. Dec. 14, 2023)	20
Zev v. Merman,	
533 N.E.2d 669 (N.Y. Court of Appeal 1988)	3
Rules and Regulations	
Code of Federal Regulations	
Title 21, sections 210-211	10
Title 21, section 211.25(b)	11
Title 21, section 211.34	

Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 4 of 25


Sentynl Therapeutics, Inc. ("Sentynl"), submits this reply (the "Reply") in support of its *Motion* for Allowance of Administrative Expense Claim (the "Motion for Allowance") and respectfully states as follows:

PRELIMINARY STATEMENT

1.	Zokinvy® (non-proprietary name, "lonafarnib"), is a <i>commercial</i> drug and the only
treatment fo	or Hutchinson-Gilford Progeria Syndrome (HGPS) and processing deficient Progeroid
Laminopath	nies (collectively, "Progeria"), which are ultra-rare, fatal, pediatric genetic diseases. ²

2. EIT⁶ and the LT argue, for their side, that Corden and Lonza also manufacture lonafarnib for non-commercial *investigational* uses. One such unapproved, investigational use is

³ See Exhibit A (flowchart of Zokinvy supply chain).



⁵ Dundon Advisers LLC, in its capacity as liquidating trustee (the "LT" or "Liquidating Trustee").

Docket No. 729. Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Motion for Allowance.

Zokinvy® (lonafarnib) is approved in the U.S., Europe, and Japan, and provided to Progeria patients around the world through compassionate use and managed access programs. *See, e.g.,* Zokinvy® approved FDA labeling (https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=956a142f-35d6-4fe3-8aef-7e4878d275ed).

⁶ EIT Pharma, Inc. (f/k/a Eiger InnoTherapeutics, Inc.) ("EIT").

Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 5 of 25


for the <u>potential</u> treatment of HDV. HDV patients have other treatment options, one product is already on the market in Europe.⁷ EIT might never obtain regulatory approval to sell its lonafarnib for HDV product commercially, and it might be less effective than existing HDV treatments.

4.	

Hepcludex® (Bulevirtide). See https://www.ema.europa.eu/en/medicines/human/EPAR/hepcludex.

⁸

Gary Broadbent, in his capacity as the Plan Administrator appointed pursuant to the Fifth Amended Joint Plan of Liquidation of Eiger Biopharmaceuticals, Inc. and its Debtor Affiliates (the "PA" or "Plan Administrator").




8.	I		
9.			

17

The Motion for Allowance raised several breaches. Some are not issues today. One, the IQVIA issue is, by and large, resolved. Though Sentynl has yet to receive the global safety database, which is itself a significant regulatory concern, EIT has stated to Sentynl that it has signed Change Orders that direct IQVIA to transfer the database. Sentynl will seek legal fees and expenses in connection with the IQVIA-related portion of its administrative expense. Two, the Zokinvy® repayment liability to France is not at issue in this contested matter. The estate reserved about \$3 million to pay Sentynl pre-closing costs because the French government seeks a refund of €2,900,225. Sentynl is still negotiating with France. Meanwhile, the estate must continue to reserve the reimbursement funds.







Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 10 of 25

14.		
15.		
16.		

Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 11 of 25

17.	
18.	

DETAILS OF THE SUPPLY CHAIN

A. Commercial Drug Manufacturing Overview

19. Zokinvy® is a *commercial* drug and the only approved treatment for Progeria, a group of ultra-rare, fatal, pediatric genetic diseases. Lonafarnib, the active ingredient in

Declaration of David Apelian in Support of the Chapter 11 Petitions and First Day Pleadings [Docket No. 19
 ¶ 7].

Objection and Response of the Liquidating Trustee and Plan Administrator to Motion for Allowance of Administrative Expense Claim of Sentynl Therapeutics, Inc. [Docket No. 777] (the "Objection").

²⁸ See Objection ¶ 1.

Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 12 of 25

Zokinvy®, has been studied for decades in other potential applications. One such application is an investigational treatment of the communicable disease HDV, a potentially larger market (depending on the infection rate), but for which alternative treatments are already either: (a) in advanced clinical trials; or (b) already commercially available in Europe.

20. Drugs in the market require compliance with Good Manufacturing Practice ("GMP") requirements, under regulations promulgated worldwide, especially the U.S. All commercial drug manufacturing <u>must</u> be performed in <u>full</u> compliance of GMP requirements. The requirements are set by the FDA and similar regulatory authorities around the world; they are not

Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 13 of 25

a liability management practice. For example, in the U.S., GMP requirements for production, packaging, and storage of commercial drugs are found in 21 C.F.R. §§ 210-211.


21. NDA/MAH holders frequently partner with CDMOs to produce drugs at scale. CDMOs have infrastructure, equipment, and expertise for raw material sourcing, formulation, packaging, and distribution, ensuring compliance with regulatory standards, and maintaining the quality of the final product. B. 22.

³⁰ See Exhibit A.



Sentynl requests that the Court take judicial notice of the following restrictive regulations:

- a. 21 C.F.R. § 211.25(b), and how it provides for every person responsible for supervising the manufacture, processing, packing, or holding of a drug product to have education, training, and experience to perform its functions to provide assurance that the drug product has the requisite safety, identity, strength, quality, and purity.
- b. 21 C.F.R. § 211.34, and how it provides similar education and training requirements for consultants advising on the manufacturing process.



31

The FDA has explained that a pharmaceutical quality system should include
appropriate processes, resources, and responsibilities to provide assurance of the quality of any
outsourced activities. ³²
26. FDA guidance illustrates the agency's expectation that the drug manufacturing
process is handled only by the NDA owner and the CDMO. ³³
"When an owner uses a
contract facility, the owner's quality unit is legally responsible for approving or rejecting drug
products manufactured by the contract facility." ³⁴ Further, "the <i>owners' quality units are</i>
ultimately responsible for ensuring that the products are manufactured in accordance with
CGMP."35
Moreover, involving additional parties in the manufacturing

See U.S. FOOD & DRUG ADMIN., Q10 PHARMACEUTICAL QUALITY SYSTEM: GUIDANCE FOR INDUSTRY (2009), https://www.fda.gov/media/71553/download. This includes assessing the "suitability and competence of potential contractors before outsourcing operations," and documenting all activities and requirements in a written agreement. *Id.* at 8.


³³ See U.S. FOOD & DRUG ADMIN., CONTRACT MANUFACTURING ARRANGEMENTS FOR DRUGS: QUALITY AGREEMENTS: GUIDANCE FOR INDUSTRY (2016), https://www.fda.gov/media/86193/download. This guidance also uses the term "both parties" to refer to all parties to a quality agreement, reflecting FDA's expectation that quality agreements are between an NDA owner and CDMO, and not any other third party. *Id.* at 6, 9, 10.

³⁴ *Id.* at 4 (emphasis added).

³⁵ *Id.* at 5 (emphasis added). "CGMP" means Current Good Manufacturing Practice.


³⁶ *Id.* at 6.

process can create hindering interdependencies and increase risk of noncompliance.³⁷




³⁷ "While manufacturing and supply chain diversity can be enablers of product availability, increasingly complex supply chains lead to interdependencies that can introduce systemic quality/manufacturing risks impacting supply chain robustness." U.S. FOOD & DRUG ADMIN., Q9(R1) QUALITY RISK MANAGEMENT: GUIDANCE FOR INDUSTRY (2023), https://www.fda.gov/media/167721/download.

³⁸ See Exhibit H



Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 18 of 25



39 See Exhibit I

Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 19 of 25


FURTHER REPLY IN SUPPORT OF MOTION FOR ALLOWANCE

	A.	
	33.	
	34.	Commercial drugs must be manufactured by GMP compliant facilities. Non-
compl	iance m	eans the drug cannot be released to the public.
	35.	
	36.	

37.			
38.		·	

Exhibit F (emphasis added).

⁴¹ See Exhibit J






C.				
41.	·			
.1.				
42.			_	
43.				

See Response of the Liquidating Trustee to Emergency Motion of Sentynl Therapeutics, Inc. for Entry of an Order (I) Setting Status Conference and Continuing Evidentiary Hearing; (II) Authorizing Additional Pages for Sentynl's Reply Brief in Support of It [Docket No. 799] (the "LT's Response to Sentynl's Emergency Motion") at ¶¶ 4, 13-16.


⁴⁶ Section 2.1(a) of the Sublicense Agreement.

⁴⁷ "A court's fundamental objective in interpreting a contract is to determine the parties' intent from the language employed and to fulfill their reasonable expectations." *Landmark Ventures, Inc. v. H5 Techs., Inc.*, 58 N.Y.S.3d 591 (N.Y. Sup. Ct. A.D. 2017).

Case 24-80040-sgj11 Doc 800 Filed 04/07/25 Entered 04/07/25 18:52:21 Desc Main Document Page 23 of 25



Sentynl requests the Court hold an evidentiary hearing and, upon presentation of evidence of a breach by the LT and damages that the Court allow Sentynl's administrative expense against the estate as shown at trial and such other and further relief as is just and necessary.



Dated: April 7, 2025 Respectfully submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP

By: /s/ Hugh M. Ray, III

Hugh M. Ray, III
Texas Bar No. 24004246
L. James Dickinson
Texas Bar No. 24105805
Reed C. Trechter
Texas Bar No. 24129454
609 Main Street, Suite 2000
Houston, TX 77002
Tel: (713) 276-7600
hugh.ray@pillsburylaw.com
james.dickinson@pillsburylaw.com
reed.trechter@pillsburylaw.com

-and-

Joshua D. Morse Four Embarcadero Center, 22nd Floor San Francisco, CA 94111-5998 Tel: (415) 983-1202 joshua.morse@pillsburylaw.com

STROMBERG STOCK, PLLC

By: /s/ Mark Stromberg

Mark Stromberg
Texas Bar No. 19408830
8350 North Central Expressway, Suite 1225
Dallas, Texas 75206
Tel: (972) 458-5353
mark@strombergstock.com

Counsel for Sentynl Therapeutics, Inc.

CERTIFICATE OF SERVICE

I certify that, on April 7, 2025, I caused a copy of the foregoing Motion to be served by the Electronic Case Filing System for the United States Bankruptcy Court for the Northern District of Texas and an unredacted copy to be emailed to the following parties.

Counsel to EIT

GOODWIN PROCTOR LLP

Kizzy Jarashow

kjarashow@goodwinlaw.com

David Chen

davidchen@goodwinlaw.com

Counsel for the LT

PORZIO, BROMBERG & NEWMAN, P.C.

Warren J. Martin Jr. WJMartin@pbnlaw.com

Rachel A. Parisi

RAParisi@pbnlaw.com

Counsel for the LT

Counsel for EIT

Jason S. Brookner

Emily F. Shanks

jbrookner@grayreed.com

eshanks@grayreed.com

GRAY REED

MCKOOL SMITH, PC

John J. Sparacino

jsparacino@mckoolsmith.com

S. Margie Venus

mvenus@mckoolsmith.com

Travis E. DeArman

tdearman@mckoolsmith.com

Associate & Assistant General Counsel for

<u>Lonza</u>

Lara Crow

lara.crow@lonza.com

Stacy Broad

stacy.broad@lonza.com

General Counsel for Corden

Naoki Takei

naoki.takei@cordenpharma.com

Richard Janovjak

richard.janovjak@cordenpharma.com

Counsel for Progeria Research Foundation

Clifford W. Carlson

Clifford.carlson@weil.com

Emma Wheeler

emma.wheeler@weil.com

/s/ Hugh M. Ray, III

Hugh M. Ray, III